Clinical trials: Advanced Adenocarcinoma
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer…
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
- Trial name
- NCT02178436
- Testing
- gemcitabine hydrochloride, Selinexor, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Mohammed Najeeb Al Hallak
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer.
- Trial name
- NCT03642067
- Testing
- Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
This phase II trial is studying how well triapine works as first-line or second-line therapy in treating patients with locally advanced or metastatic adenocarcinoma (cancer) of the pancreas.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00085371
- Testing
- triapine
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
HLRCC, Sporadic Papillary Renal Cell Cancer
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Background: At the present time, there are no drugs that have been proven to work in patients with papillary kidney cancer that has spread (metastasized) beyond the kidneys.
- Trial name
- NCT01130519
- Testing
- Bevacizumab, Erlotinib
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer, Colon Cancer
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
In this Phase I/II clinical trial, the investigators seek to pilot the addition of hydroxychloroquine (HCQ) to the standard front-line therapy of colorectal cancer, FOLFOX/bevacizumab.
- Conditions
- Rectal Cancer, Colon Cancer, Metastasis, Adenocarcinoma
- Trial name
- NCT01206530
- Testing
- Hydroxychloroquine, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Randomized phase III trial to compare the effectiveness of irinotecan with that of combination chemotherapy in treating patients who have advanced colorectal cancer that has not responded to previous treatment.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00005036
- Testing
- irinotecan hydrochloride, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
- Conditions
- Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04242199
- Testing
- INCB099280
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 182 people
- Sponsor
- Incyte Corporation
Cancer
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
OBJECTIVES: This study proposes to evaluate the feasibility of delivery of this treatment in terms of toxicity. If toxicity is not acceptable, the treatment is not feasible.
- Trial name
- NCT00983541
- Testing
- Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Hepatocellular Carcinoma
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
At present, there is no standard treatment plan for hepatocellular carcinoma after the progress of first-line target immunotherapy.
- Trial name
- NCT07078305
- Testing
- Regorafenib and tislelizumab, Regorafenib
- Volunteers
- 134 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma (HCC)
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
Tumor-draining lymph nodes play an important role in anti-tumor immune responses. In patients with hepatocellular carcinoma (HCC), however, the relationship between regional lymph node metastasis (LNM) and immunotherapy-based…
- Trial name
- CHANCE2421 (NCT06876753)
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhongda Hospital
Kidney Neoplasms, Metastatic Renal Cell Cancer
Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma
Patients who are candidates for first line treatment with Sunitinib 50mg 4/6 regimen in accordance with the Marketing Authorisation who meet the inclusion/exclusion criteria will be offered participation in this study during the…
- Trial name
- SURF (NCT02689167)
- Testing
- Sunitinib
- Where
- France
- Volunteers
- 226 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hepatocellular Carcinoma (HCC)
A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma
This is an early-phase study testing a new combination treatment for cancer. participants will receive a type of radiation therapy called MRI-guided or CT-guided radiotherapy, depending on which imaging method is safe for them.
- Trial name
- PRISM (NCT06994299)
- Testing
- Radiation Therapy, Tremelimumab, Durvalumab
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Metastatic Renal Cell Carcinoma, Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed
Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
This is an open-label, multicenter dose-escalation phase I study using a 3+3+3 design (i.e., 3 to 9 patients per dose level) in patients with mRCC or others advanced refractory solid tumors.
- Trial name
- PARASOL (NCT01202032)
- Testing
- Association of Bevacizumab (BVC)+ Pazopanib (PZP)
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Centre Leon Berard
Gastric Adenocarcinoma
Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score
The researching subject is aimed to obtain the clinical evidences (including real benefits， risks ,etc. ) of traditional Chinese medicine in the treatment of advanced gastric cancer by compared with the outcomes that not accept…
- Trial name
- ESCOTCMAGCPS (NCT02781285)
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Hepatocellular Carcinoma (HCC)
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Study Design: This is a pilot study with a single arm in a single centre assessing safety and efficacy of durvalumab in combination with bevacizumab and HAIC followed by SBRT.
- Trial name
- NCT07012798
- Testing
- Durvalumab, Bevacizumab, HAIC of FOLFOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Solid Tumor
A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
This is a Phase I clinical study of HS-20108. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of intravenous HS-20108 in patients with advanced solid tumors.
- Trial name
- NCT06936735
- Testing
- HS-20108 Monotherapy
- Where
- China
- Volunteers
- 502 people
- Sponsor
- Hansoh BioMedical R&D Company
Gastric Adenocarcinoma
Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma
1. Target population:locally advanced gastric adenocarcinoma (LAGC, cT2~3/N+M0,or cT4aN+M0);no previous chemo or radio therapy. 2. Primary objective:Response rate of XELOX in the neoadjuvant setting of LAGC.
- Trial name
- Neo-Classic (NCT01880632)
- Testing
- XELOX
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Shanghai Zhongshan Hospital
Small Bowel Adenocarcinoma
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
The study regimen will be administered on an outpatient basis and all medications are administered intravenously (IV). Subjects will receive treatment on Day 1 and Day 15 of each 28-day cycle consisting of the following…
- Trial name
- NCT06835387
- Testing
- Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tiago Biachi de Castria
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.